Equities research analysts predict that Compugen Ltd. (NASDAQ:CGEN) will announce earnings of ($0.11) per share for the current fiscal quarter, Zacks reports. Zero analysts have made estimates for Compugen’s earnings. The lowest EPS estimate is ($0.11) and the highest is ($0.10). Compugen posted earnings of ($0.05) per share during the same quarter last year, which indicates a negative year over year growth rate of 120%. The business is scheduled to announce its next quarterly earnings results on Wednesday, November 6th.
According to Zacks, analysts expect that Compugen will report full-year earnings of ($0.45) per share for the current fiscal year, with EPS estimates ranging from ($0.46) to ($0.43). For the next year, analysts forecast that the company will report earnings of ($0.41) per share, with EPS estimates ranging from ($0.44) to ($0.37). Zacks’ EPS averages are a mean average based on a survey of analysts that that provide coverage for Compugen.
Compugen (NASDAQ:CGEN) last announced its quarterly earnings data on Monday, August 5th. The biotechnology company reported ($0.10) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.14) by $0.04.
CGEN has been the subject of a number of research analyst reports. ValuEngine downgraded Compugen from a “hold” rating to a “sell” rating in a report on Wednesday, October 2nd. Zacks Investment Research raised Compugen from a “hold” rating to a “buy” rating and set a $4.50 price target for the company in a report on Thursday.
A number of institutional investors and hedge funds have recently made changes to their positions in the stock. ARK Investment Management LLC boosted its holdings in Compugen by 3.2% in the second quarter. ARK Investment Management LLC now owns 8,496,641 shares of the biotechnology company’s stock valued at $32,627,000 after purchasing an additional 267,086 shares in the last quarter. Nikko Asset Management Americas Inc. raised its holdings in shares of Compugen by 84.0% in the 2nd quarter. Nikko Asset Management Americas Inc. now owns 1,631,037 shares of the biotechnology company’s stock worth $6,263,000 after acquiring an additional 744,447 shares during the last quarter. Morgan Stanley raised its holdings in shares of Compugen by 2.1% in the 2nd quarter. Morgan Stanley now owns 1,035,175 shares of the biotechnology company’s stock worth $3,975,000 after acquiring an additional 21,368 shares during the last quarter. Taylor Frigon Capital Management LLC raised its holdings in shares of Compugen by 11.5% in the 2nd quarter. Taylor Frigon Capital Management LLC now owns 760,424 shares of the biotechnology company’s stock worth $2,920,000 after acquiring an additional 78,278 shares during the last quarter. Finally, Renaissance Technologies LLC raised its holdings in shares of Compugen by 20.7% in the 2nd quarter. Renaissance Technologies LLC now owns 557,800 shares of the biotechnology company’s stock worth $2,142,000 after acquiring an additional 95,500 shares during the last quarter. 29.95% of the stock is owned by hedge funds and other institutional investors.
Shares of Compugen stock traded down $0.16 on Monday, reaching $4.01. 59,064 shares of the company were exchanged, compared to its average volume of 170,554. The stock’s 50 day moving average price is $4.10 and its 200-day moving average price is $3.69. The company has a debt-to-equity ratio of 0.11, a current ratio of 5.38 and a quick ratio of 5.38. The company has a market cap of $205.69 million, a P/E ratio of -9.78 and a beta of 2.60. Compugen has a 1-year low of $2.00 and a 1-year high of $4.50.
Compugen Ltd., a therapeutic discovery company, engages in the research, development, and commercialization of therapeutic and product candidates in Israel and Europe. The company's therapeutic pipeline consists of immuno-oncology programs against novel drug targets in the areas of unmet medical needs in various cancer types and patient populations.
Featured Story: Convertible Shares
Get a free copy of the Zacks research report on Compugen (CGEN)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Compugen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compugen and related companies with MarketBeat.com's FREE daily email newsletter.